Photodermatol Photoimmunol Photomed. 2025 Nov;41(6):e70059. doi: 10.1111/phpp.70059.
ABSTRACT
INTRODUCTION: Vitiligo, a common depigmentation disorder, is often treated with phototherapy. 308-nm monochromatic excimer lamp/laser (308-nm MEL) is typically administered in hospitals, whereas 308-nm light-emitting diodes (308-nm LED) offer a home-based alternative. This study compared the efficacy and safety of home-based 308-nm LED with hospital-based 308-nm MEL in pediatric vitiligo.
METHODS: A retrospective analysis of 75 pediatric vitiligo patients treated with home-based 308-nm LED or hospital-based 308-nm MEL was conducted. Efficacy (repigmentation > 50%) and adverse events were evaluated after 16, 32, and 48 sessions. Statistical analyses were performed using SPSS 25.0.
RESULTS: After 48 sessions, hospital-based 308-nm MEL showed higher efficacy rates (79.5%) than home-based 308-nm LED (38.9%, p < 0.001). However, efficacy was similar when cumulative doses were comparable (p > 0.05). Adverse events were more frequent in the home-based group (63.9% vs. 30.8%, p = 0.029), likely due to cautious dose adjustments. Shorter disease duration and stable disease correlated with better outcomes (p < 0.05).
CONCLUSION: Home-based 308-nm LED is a viable alternative to hospital-based 308-nm MEL for pediatric vitiligo when cumulative doses are similar. However, higher adverse events in home-based therapy highlight the need for better patient education and professional guidance. AI and digital platforms could enhance the safety and efficacy of home-based phototherapy.
PMID:41074622 | DOI:10.1111/phpp.70059
